Chelsea Therapeutics International Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Possible Breaches Of Fiduciary Duty By The Officers And Directors Of Chelsea Therapeutics International, Ltd.
Former United States Securities and Exchange Commission attorney
Briscoe, founder of
Briscoe Law Firm, PLLC, and the securities litigation firm of
Taylor, LLP announce that the firms are...
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that the firms are investigating legal claims against the officers and Board of Directors of Chelsea Therapeutics International, Ltd. (“Chelsea” or “CHTP”) (NASDAQ: CHTP) related to potential securities violations between June 9, 2011 and February 17, 2012 (the “Class Period”). If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at firstname.lastname@example.org, or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you. In a recently filed federal class action complaint, Chelsea and certain of its officers and directors were charged with violating the Securities Exchange Act of 1934. Chelsea is a biopharmaceutical company that had been developing the drug Northera (“Droxidopa”) for use in treating neurogenic orthostatic hypotension (“NOH”) in patients with primary autonomic failure, including Parkinson’s disease. The complaint alleges that during the Class Period, defendants made material misstatements and omissions concerning (i) the safety and efficacy of Droxidopa for patients with NOH; (ii) the results of the Phase III testing of Droxidopa for patients with NOH; and (iii) the post-marketing events in Japan and the likelihood of FDA approval of Droxidopa for patients with NOH in light of the known adverse material facts concerning Droxidopa for patients with NOH. It is further alleged that these misstatements and omissions artificially inflated Chelsea’s common stock price during the Class Period, so that when the true facts concerning the safety and efficacy of Droxidopa were revealed, Chelsea’s common stock price declined dramatically. Specifically, Chelsea’s stock price dropped from $4.99 per share on February 13, 2012 to $2.64 per share on February 21, 2012.
Chelsea CEO Joe Oliveto and his team deserve a lot of credit for cleaning up some messy Northera clinical trials, scoring at the FDA advisory panel, securing the drug's approval and now delivering on the exit strategy that everyone wanted.
Wedbush believed that Chelsea Therapeutics International is an attractive acquisition or partnership target for multiple pharmaceutical companies because of the approval of NortheraThe stock price of ...